In summary, modulation of galectin-3, an emerging all-out player in metabolic disorders, deserves further scientific attention as a novel marker and therapeutic avenue for the control of metabolic disorders such as diabetes and obesity. This evidence concerns the gene LGALS3 and Other metabolic disease.